Renhe Pharmacy released its 2026 interim report. First-half net profit attributable to the parent was 292 million yuan, up 0.5% year on year. Operating revenue was 2.09 billion yuan, up 5.9% year on year. Net profit attributable to the parent excluding non-recurring items was 253 million yuan, up 22.4% year on year. Net operating cash flow was 572 million yuan, down 14.8% year on year. Second-quarter operating revenue was 962 million yuan, down 2.8% year on year, while net profit attributable to the parent was 152 million yuan, up 20.2% year on year. The company said its pharmaceutical business is mainly over-the-counter products, which account for 80% of drug revenue, and traditional Chinese medicine products account for about 47% of drug revenue.
Renhe Pharmacy Co LtdNet profit up 0.5% but revenue growth modest and cash flow down; mixed results.
